A new standard for results in metabolic care
A groundbreaking approach, grounded in smarter nutrition and personalized support.
Our members are reversing their condition and taking back their lives
Virta’s evidence-based approach is helping our members do things they haven’t done in years and recapture the lives they deserve.
Chris has rediscovered his love of BMX riding, and now shares this passion with his daughter when they go to the bike park every week.
Chris
- Reduced HbA1c by 1.7%, below the prediabetes threshold
- Lost 110 lbs.
- Eliminated all diabetes medications
“I’m feeling incredible, and the best part is that I can truly enjoy riding BMX with my daughter again.”
Marcie rediscovered energy she hadn't felt in decades. And no longer requiring diabetes or blood pressure medications lifted a huge weight from her shoulders
Marcie
- Lost 100 lbs.
- Eliminated all diabetes and blood pressure medications
- Reduced A1c from 6.1% to 4.8%
“Now my family has trouble keeping up with me. I feel like I’m half my age. I have endless energy.”
Linda had tried everything, found Virta, and decided “one more try with something completely different.” The results have surprised her and she hasn't looked back.
Linda
- Lost 65 lbs.
- Reduced medications
- Experiences “non-scale” victories daily
“I finally fit comfortably behind the steering wheel in my car and put the tray table down on an airplane. It feels like a miracle.”
Virta’s provider-led approach delivers unmatched outcomes
Our landmark clinical trial provides the foundation for reversal of chronic conditions, and resets the expectations for metabolic care.
A1c Reduction
1.3%
Virta is different because our members living with type 2 diabetes see substantial improvement in blood sugar, while actually reducing the need for diabetes medications.¹
Diabetes Prevention
97%
Over a two year period, 97% people in our trial did not progress to T2D, with many reversing their condition entirely.²
Medication Reduction
63%
Clinical trial participants eliminated nearly two-thirds of diabetes prescriptions, with 60% of people eliminating all diabetes meds excluding metformin at one year.¹
Weight Loss
31 lbs
Virta's nutritional therapy and provider-led approach helps people lose weight—a lot of it—12% on average (just over 30 pounds) at one year.¹
Whole-person health, redefined
Reversal means health transformation. Addressing the root cause delivers on the true promise of whole-person health.
Depression Improvement
29%
Reduction in people meeting clinical cutoff for depression³
Knee Pain Reduction
46%
People with clinically meaningful knee pain improvement⁴
Inflammation Reduction
39%
Average reduction in markers of inflammation¹
ASCVD Risk Score
12%
More than 20 CVD markers improve at one year, leading to a 12% improvement in ASCVD risk score.⁵
Side benefits, not side effects
From liver function to sleep to blood pressure and more, members see improvements across the board.¹,⁵,⁸,⁹
- Improved sleep
- Improved blood pressure
- Improved liver function
- Improved triglycerides
Citations by the American Diabetes Association
Since 2019, Virta Health research has been cited in the ADA standards of medical care, which include low-carbohydrate nutrition as a first-line therapy for diabetes treatment.
Results that last
Results happen fast, and behavior change is sustained through our high-touch, individualized approach.¹,⁶,⁷
Retention at One Year
Metformin Adherence
Weight Loss Programs
2-6x
Higher retention than benchmarks
Patients stick with Virta at a much higher rate than most other medication or nutritional programs.
Virta is leading the way on diabetes reversal research
Our research demonstrates what is possible when members have a solution that actually works for them.
See researchCitations and Footnotes
- Hallberg SJ, McKenzie AL, Williams P, et al. Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at One Year: An Open Label, Non-Randomized, Controlled Study. Diabetes Ther. 2018. DOI: 10.1007/s13300-018-0373-9. Medication and weight-loss is for people living with type 2 diabetes and completing 1 year. Medication reduction refers to the percent of total diabetes prescriptions eliminated, excluding metformin.
- McKenzie AL, Athinarayanan SJ, McCue JJ, Adams RN, Keyes M, McCarter JP, Volek JS, Phinney SD, Hallberg SJ. Type 2 Diabetes Prevention Focused on Normalization of Glycemia: A Two-Year Pilot Study. Nutrients. 2021; 13(3):749.
- Adams RN, Athinarayanan SJ, McKenzie AL, Hallberg SJ, McCarter JP, Phinney SD, Gonzalez JS. Depressive symptoms improve over 2 years of type 2 diabetes treatment via a digital continuous remote care intervention focused on carbohydrate restriction. J Behav Med. 2022
- Lyman, K.S., Athinarayanan, S.J., McKenzie, A.L. et al. Continuous care intervention with carbohydrate restriction improves physical function of the knees among patients with type 2 diabetes: a non-randomized study. BMC Musculoskelet Disord 23, 297 (2022).
- Bhanpuri, N.H., Hallberg, S.J., Williams, P.T. et al. Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year: an open label, non-randomized, controlled study. Cardiovasc Diabetol 17, 56 (2018) doi:10.1186/s12933-018-0698-8
- Campbell, DJT, Campbell, DB, Ogundeji, Y, et al. First-line pharmacotherapy for incident type 2 diabetes: Prescription patterns, adherence and associated costs. Diabet Med. 2021; 38:e14622. https://doi.org/10.1111/dme.14622
- Martin CK, Talamini L, Johnson A, Hymel AM, Khavjou O. Weight loss and retention in a commercial weight-loss program and the effect of corporate partnership. Int J Obes (Lond). 2010;34(4):742–750. doi:10.1038/ijo.2009.276
- Siegmann MJ, Athinarayanan SJ, Hallberg SJ, et al. Improvement in Patient-Reported Sleep in Type 2 Diabetes and Prediabetes Participants Receiving a Continuous Care Intervention with Nutritional Ketosis. Sleep Medicine. 2019; 55: 92 - 99. doi: 10.1016/j.sleep.2018.12.014
- Vilar-Gomez E, Athinarayanan SJ, Adams RN, et al Post hoc analyses of surrogate markers of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, non-randomised controlled study BMJ Open 2019;9:e023597. doi: 10.1136/bmjopen-2018-023597